Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics Plc ADR (NQ: BCYC )

13.49 -6.62 (-32.92%)
Streaming Delayed Price Updated: 11:00 AM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bicycle Therapeutics Plc ADR

< Previous 1 2 3 4 Next >
Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Programs at the SITC 36th Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal for ImmunoTherapy of Cancer
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Pricing of Upsized Public Offering of $175 Million of American Depositary Shares
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Proposed $125,000,000 Public Offering of American Depositary Shares
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Present BT5528 Interim Phase I Data at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics
From Bicycle Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.